VistaGen Therapeutics, Inc.
NASDAQ: VTGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shawn K. Singh
- Employees
- 48
- Headquarters
- South San Francisco, United States
- IPO year
- 2011
- Market cap
- $21.8M
- Website
- https://www.vistagen.com
Loading VTGN…
Loading profile data…Frequently asked questions about VTGN
What does VistaGen Therapeutics, Inc. (VTGN) do?
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III tria...
Where does VTGN trade?
VistaGen Therapeutics, Inc. (VTGN) trades on the NASDAQ Capital Market.
What sector is VTGN in?
VistaGen Therapeutics, Inc. (VTGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of VistaGen Therapeutics, Inc.?
Shawn K. Singh is the chief executive officer of VistaGen Therapeutics, Inc. (VTGN).
Where is VistaGen Therapeutics, Inc. headquartered?
VistaGen Therapeutics, Inc. is headquartered in United States.
Does VTGN pay a dividend?
VistaGen Therapeutics, Inc. (VTGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VTGN go public?
VistaGen Therapeutics, Inc. (VTGN) completed its initial public offering in 2011.